Clearstead Advisors, LLC Coherus Bio Sciences, Inc. Transaction History
Clearstead Advisors, LLC
- $6.94 Billion
- Q2 2025
A detailed history of Clearstead Advisors, LLC transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Clearstead Advisors, LLC holds 1,780 shares of CHRS stock, worth $2,919. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,780Holding current value
$2,919% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CHRS
# of Institutions
119Shares Held
58.2MCall Options Held
89.3KPut Options Held
31K-
Black Rock Inc. New York, NY11.8MShares$19.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.6MShares$17.3 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA5.1MShares$8.36 Million0.22% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$4.98 Million0.09% of portfolio
-
Geode Capital Management, LLC Boston, MA2.68MShares$4.39 Million0.0% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $127M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...